Mortality risk of mirtazapine: Guilt by association?

JAMA Psychiatry

Volumn 71, Issue 5, 2014, Pages 585-586

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; LETTER; MAINTENANCE THERAPY; MEDICATION COMPLIANCE; NEUROTOXICITY; PSYCHOSIS; RECURRENCE RISK; REMISSION; SCHIZOPHRENIA; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 84900455465     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.191     Document Type: Letter

References (5)

1. Khan A, Faucett J, Morrison S, BrownWA. Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. JAMA Psychiatry. 2013;70(10):1091-1099.
2. Cheeta S, Schifano F, Oyefeso A,Webb L, Ghodse AH. Antidepressantrelated deaths and antidepressant prescriptions in England andWales, 1998-2000. Br J Psychiatry. 2004;184:41-47.
3. Cardamone L, SalzbergMR, O'Brien TJ, Jones NC. Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol. 2013;168(7):1531-1554.
4. Berling I, Isbister GK. Mirtazapine overdose is unlikely to cause major toxicity. Clin Toxicol (Phila). 2014;52(1):20-24.
5. Bronstein AC, Spyker DA, Cantilena LR Jr., Rumack BH, Dart RC. 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila). 2012;50(10):911-1164.